Evidence-based truths about the benefit of cancer screening.
作者信息
Wilkinson Anna N
机构信息
Ottawa, Ont.
出版信息
Can Fam Physician. 2024 May;70(5):296. doi: 10.46747/cfp.7005296.
Abstract
摘要
相似文献
1
Evidence-based truths about the benefit of cancer screening.
Can Fam Physician. 2024 May;70(5):296. doi: 10.46747/cfp.7005296.
2
Patient Perspectives on Primary HPV Testing for Routine Cervical Cancer Screening.
J Gen Intern Med. 2020 Mar;35(3):956-958. doi: 10.1007/s11606-019-05175-4. Epub 2019 Jul 16.
3
Population-Based Precision Cancer Screening-Letter.
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):975. doi: 10.1158/1055-9965.EPI-16-0903. Epub 2017 May 15.
4
Higher mammography screening costs without appreciable clinical benefit: the case of digital mammography.
J Natl Cancer Inst. 2014 Jul 16;106(8). doi: 10.1093/jnci/dju191. Print 2014 Aug.
5
America, We Are Confused: The Updated U.S. Preventive Services Task Force Recommendation on Colorectal Cancer Screening.
Ann Intern Med. 2017 Jan 17;166(2):139-140. doi: 10.7326/M16-1805. Epub 2016 Nov 8.
6
Increasing Colorectal Cancer Screening in Health Care Systems Using Evidence-Based Interventions.
Prev Chronic Dis. 2018 Aug 9;15:E100. doi: 10.5888/pcd15.180029.
7
Colorectal cancer screening in an expanding panorama of screening programmes.
Best Pract Res Clin Gastroenterol. 2010 Aug;24(4):521-7. doi: 10.1016/j.bpg.2010.04.006.
8
Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.
J Natl Cancer Inst. 2014 Mar;106(3):dju010. doi: 10.1093/jnci/dju010. Epub 2014 Mar 4.
9
How best to determine the mortality benefit from screening mammography: dueling results and methodologies from Canada.
J Natl Cancer Inst. 2014 Oct 1;106(11). doi: 10.1093/jnci/dju317. Print 2014 Nov.
10
Integrating personalised genomics into risk stratification models of population screening for colorectal cancer.
Aust N Z J Public Health. 2017 Feb;41(1):3-4. doi: 10.1111/1753-6405.12587. Epub 2016 Oct 23.
引用本文的文献
1
Response.
Can Fam Physician. 2024 May;70(5):296-297. doi: 10.46747/cfp.7005296_1.
本文引用的文献
1
Analysis of Breast Cancer Mortality in the US-1975 to 2019.
JAMA. 2024 Jan 16;331(3):233-241. doi: 10.1001/jama.2023.25881.
2
Debunking myths about screening: How to screen more judiciously.
Can Fam Physician. 2023 Nov;69(11):767-771. doi: 10.46747/cfp.6911767.
3
Five-year cancer survival by stage at diagnosis in Canada.
Health Rep. 2023 Jan 18;34(1):3-15. doi: 10.25318/82-003-x202300100001-eng.
4
Projected estimates of cancer in Canada in 2022.
CMAJ. 2022 May 2;194(17):E601-E607. doi: 10.1503/cmaj.212097.
5
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2.
6
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Lancet Oncol. 2021 Aug;22(8):1139-1150. doi: 10.1016/S1470-2045(21)00288-6.
7
Persistent Untreated Screening-Detected Breast Cancer: An Argument Against Delaying Screening or Increasing the Interval Between Screenings.
J Am Coll Radiol. 2017 Jul;14(7):863-867. doi: 10.1016/j.jacr.2017.01.038. Epub 2017 Apr 28.
Zotero 插件